Trospium Chloride Capsule, Extended Release
Product Images NDC 72162-1106

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 72162-1106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure of Trospium Chloride showing the molecular composition including the tropanium ion with chloride and the diphenyl carboxylate moiety.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting plasma concentration (ng/mL) over time (hours post-dose) for Trospium Chloride Extended-Release Capsules 60 mg. The graph shows plasma concentration increasing to a peak around 4 hours post-dose, followed by a gradual decline up to 24 hours, with error bars indicating variability at each time point.*

FDA Label Image

Figure 2 (Image 03)

A line graph comparing the average change (± standard error) over time between placebo and Trospium Chloride extended-release capsules. The x-axis represents time in weeks (0, 1, 4, and 12), and the y-axis shows average change values. Data points for placebo and Trospium Chloride ER groups are indicated with solid and open circles, respectively, with accompanying p-values highlighting statistical significance at various time points.*

FDA Label Image

Figure 3 (Image 04)

A line graph comparing average change (± standard error) over time between placebo and Trospium Chloride Extended-Release Capsules. The x-axis shows time points at 0, 1, 4, and 12, while the y-axis represents average change values. The graph includes p-values indicating statistical significance at time points 1, 4, and 12.*

FDA Label Image

Figure 4 (Image 05)

A line graph comparing average change (+/- standard error) over time between placebo (N=276) and Trospium Chloride Extended-Release Capsules (N=267). The x-axis represents time points at 0, 1, 4, and 12 weeks, while the y-axis shows average change values from 0.0 to -3.5. Statistical significance values (p-values) are noted at 1, 4, and 12 weeks on the graph.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing the average change with standard error over time between placebo and Trospium Chloride Extended-Release Capsules groups. The y-axis represents average change, and the x-axis denotes time points at 0, 1, 4, and 12 weeks. Trospium Chloride shows a greater decrease than placebo, with p-values less than 0.001 at all measured intervals.*

FDA Label Image

Label (Lbl721621106)

Label for Trospium Chloride Extended-Release Capsules, 60 mg strength, in a 30-capsule package. The label includes storage instructions, the note to keep medication out of reach of children, and states it is Rx only. It is relabeled by Bryant Ranch Prepack, Inc. and manufactured by Sidmak Laboratories Pvt. Ltd. The NDC number 72162-1106-3 is displayed with barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.